Mixing versus matching booster vaccines: A longitudinal humoral immune kinetics against Omicron in a Malaysian cohort - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparing Booster Vaccine Strategies: A Longitudinal Study of Humoral Immune Response to Omicron in a Malaysian Population

  • By

  • Ashwathy Varadarajan Thundakattil

  • Rekha Prabhu

  • Girish Prabhu

  • Muthuvel Mani

  • Somsubhra De

  • Htoo Htoo Kyaw Soe

  • Charlotte Patrick Arjunan

  • Sumandeep Kaur Chahl

  • Debban A.L Ramesh

  • Ng Jian Chen

  • Soh Pei Qi

  • Jaayshree a.p Prakash

  • Nikhytha a.p Chandran

  • Mila Nu Nu Htay

  • Sabyasachi Das

  • September 4, 2026

Share

  • 1

    The study evaluated longitudinal humoral immune responses to COVID-19 booster vaccines during the Omicron outbreak in Malaysia.

  • 2

    Participants received 5 booster regimens, including 3 homologous and 2 heterologous vaccine combinations.

  • 3

    Of 332 participants included in 24-week follow-up, 268 completed follow-up and 190 were included in the longitudinal immunogenicity analysis after exclusions, including new SARS-CoV-2 infections.

  • 4

    Blood samples were collected before boosting and at weeks 2, 4, 8, 12, 16, and 24, with plasma assessed for anti-S IgG and anti-RBD antibodies and Omicron neutralization evaluated using a surrogate virus neutralization test.

  • 5

    The study compared antibody kinetics and Omicron neutralization across booster strategies in Malaysian healthcare professionals and medical students.

Original Source(s)

Mixing versus matching booster vaccines: A longitudinal humoral immune kinetics against Omicron in a Malaysian cohort

  • by Ashwathy Varadarajan Thundakattil, Rekha Prabhu, Girish Prabhu, Muthuvel Mani, Somsubhra De, Htoo Htoo Kyaw Soe, Charlotte Patrick Arjunan, Sumandeep Kaur Chahl, Debban A.L Ramesh, Ng Jian Chen, Soh Pei Qi, Jaayshree a.p Prakash, Nikhytha a.p Chandran, Mila Nu Nu Htay, Sabyasachi Das

  • September 4, 2026

Related Content

Impact of the COVID-19 pandemic on the association between sepsis etiology and mortality among ICU patients in France

Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasons

Extended antiviral therapy may not improve long COVID

Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.